{
  "name": "Short acting beta agonist inhalers",
  "title": "Short acting beta agonist (SABA) inhalers compared with prescribing of inhaled corticosteroid inhalers and SABA inhalers",
  "description": "Number of short acting beta agonist (SABA) inhalers - salbutamol and terbutaline - compared with number of all inhaled corticosteroid inhalers and SABA inhalers",
  "numerator_short": "SABA quantity",
  "denominator_short": "ICS and SABA quantity",
  "y_label": "Percentage of inhalers (ICS and SABA) prescribed as SABA",
  "why_it_matters": [
    "The <a href='https://www.nice.org.uk/guidance/ng245/2024  target='_Blank'>BTS/NICE/SIGN guidance</a> ",
    "has updated guidance on use of short acting beta agonists (SABAs), and states ",
    "<a href='https://www.nice.org.uk/guidance/ng245/chapter/Recommendations#principles-of-pharmacological-treatment  target='_Blank'><i>do not prescribe short-acting beta<sub>2</sub> agonists to people of any age ",
    "with asthma without a concomitant prescription of an ICS</a>.</i>  In addition, it also recommends that patients aged 12 and over with uncontrolled asthma (e.g. needing a reliever ",
    "3 or more days a week) <a href='https://www.nice.org.uk/guidance/ng245/chapter/Recommendations#pharmacological-management-in-people-aged-12-and-over' target='_Blank'>should have their treatment changed to a non SABA-based regimen</a>.</p>",
    "<p><a href='https://www.rcplondon.ac.uk/projects/outputs/why-asthma-still-kills' target='_Blank'>Why Asthma Still Kills</a> reports that high use of SABAs (salbutamol and terbutaline) and poor adherence to ",
    "inhaled corticosteroids in asthma suggests poor control - these patients should be reviewed regularly to ensure good control.</p>",
    "<p>The <a href='https://www.england.nhs.uk/long-read/national-medicines-optimisation-opportunities-2023-24/#11-optimising-inhaler-use-to-improve-respiratory-outcomes-and-reduce-carbon-emissions' target='_Blank'>",
    "NHS England National Medicines Optimisation Opportunities for 2023/24</a> identify improving patient outcomes from the use of inhalers as an area for improvement.</p>"
  ],
  "tags": [
    "core",
    "respiratory",
    "opportunities",
    "safety"
  ],
  "url": null, 
  "is_percentage": true,
  "is_cost_based": false,
  "low_is_good": true,
  "numerator_type": "custom",
  "numerator_columns": "SUM(p.quantity/adj.qtyadj) AS numerator",
  "numerator_from": [
    "{hscic}.normalised_prescribing p ",
    "INNER JOIN {measures}.vw__inhaler_quantity_adjustment as adj ON p.bnf_code = adj.bnf_code AND p.month = adj.date -- joins prescribing data to view for form_route and adjustment where quantity = puffs not inhalers  \n"
    ],
  "numerator_where": [
    "adj.form_route IN ('pressurizedinhalation.inhalation', 'powderinhalation.inhalation', 'inhalationsolution.inhalation')",
    "AND ( \n",
    "p.bnf_code LIKE '0301011R0%' -- Salbutamol \n",
    "OR p.bnf_code LIKE '0301011V0%') -- Terbutaline"
  ],
  "denominator_type": "custom",
  "denominator_columns": "SUM(p.quantity/adj.qtyadj) AS denominator",
  "denominator_from": [
    "{hscic}.normalised_prescribing p ",
    "INNER JOIN {measures}.vw__inhaler_quantity_adjustment as adj ON p.bnf_code = adj.bnf_code AND p.month = adj.date -- joins prescribing data to view for form_route and adjustment where quantity = puffs not inhalers  \n"
    ],
  "denominator_where": [
    "adj.form_route IN ('pressurizedinhalation.inhalation', 'powderinhalation.inhalation', 'inhalationsolution.inhalation')",
    "AND ( \n",
    "p.bnf_code LIKE '0301011R0%' -- Salbutamol \n",
    "OR p.bnf_code LIKE '0301011V0%' -- Terbutaline \n" ,
    "OR p.bnf_code LIKE '0302%') -- Corticosteroids (Respiratory)"
  ],
  "authored_by": "richard.croker@phc.ox.ac.uk",
  "checked_by": "",
  "date_reviewed": "2024-12-02",
  "next_review": "2025-12-02",
  "measure_complexity": "medium",
  "measure_type": "dmd",
  "radar_exclude": false
}
